As of 2025-05-24, the EV/EBITDA ratio of Collplant Biotechnologies Ltd (CLGN) is -0.63. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CLGN's latest enterprise value is 10.19 mil USD. CLGN's TTM EBITDA according to its financial statements is -16.21 mil USD. Dividing these 2 quantities gives us the above CLGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 2.8x - 4.9x | 3.5x |
| Forward P/E multiples | 2.8x - 5.3x | 3.5x |
| Fair Price | (2.92) - (5.84) | (3.92) |
| Upside | -251.5% - -402.7% | -302.9% |
| Date | EV/EBITDA |
| 2025-02-28 | -1.74 |
| 2025-02-27 | -1.74 |
| 2025-02-26 | -1.74 |
| 2025-02-25 | -1.60 |
| 2025-02-24 | -1.57 |
| 2025-02-21 | -1.72 |
| 2025-02-20 | -1.72 |
| 2025-02-19 | -1.80 |
| 2025-02-14 | -1.81 |
| 2025-02-13 | -1.93 |
| 2025-02-12 | -1.87 |
| 2025-02-10 | -1.77 |
| 2025-02-07 | -1.85 |
| 2025-02-06 | -1.89 |
| 2025-02-05 | -1.91 |
| 2025-02-04 | -1.93 |
| 2025-02-03 | -1.90 |
| 2025-01-31 | -1.89 |
| 2025-01-30 | -1.92 |
| 2025-01-29 | -1.98 |
| 2025-01-28 | -1.91 |
| 2025-01-27 | -1.92 |
| 2025-01-24 | -1.89 |
| 2025-01-23 | -2.05 |
| 2025-01-22 | -2.09 |
| 2025-01-21 | -2.09 |
| 2025-01-17 | -2.11 |
| 2025-01-16 | -2.10 |
| 2025-01-15 | -2.08 |
| 2025-01-14 | -1.98 |
| 2025-01-13 | -2.04 |
| 2025-01-10 | -2.23 |
| 2025-01-08 | -2.35 |
| 2025-01-07 | -2.42 |
| 2025-01-06 | -2.38 |
| 2025-01-03 | -2.24 |
| 2025-01-02 | -1.96 |
| 2024-12-31 | -1.81 |
| 2024-12-30 | -1.83 |
| 2024-12-27 | -1.79 |
| 2024-12-26 | -1.79 |
| 2024-12-24 | -1.74 |
| 2024-12-23 | -1.69 |
| 2024-12-20 | -1.67 |
| 2024-12-19 | -1.86 |
| 2024-12-18 | -1.89 |
| 2024-12-17 | -1.84 |
| 2024-12-16 | -1.82 |
| 2024-12-13 | -1.87 |
| 2024-12-12 | -2.01 |